BioMedNewsBreaks

FridayFeb 14, 2020 2:26 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names New Member to Board of Directors

Predictive Oncology (NASDAQ: POAI) recently announced the appointment of Pam Prior, CPA, to the company’s Board of Directors. In addition to holding a seat on the board, Prior will also chair the company’s audit committee. An article further discussing the company reads, “Prior, 57, joins POAI’s Board of Directors with 35 years of experience in accounting, mainly in management as CFO or controller. As the founder and CEO of Priorities Group Inc., a provider of CFO services to small and mid-sized businesses, she has served as a CFO to a number of companies, including Gentris Corp., a private pharmacogenomics company…

Continue Reading

FridayFeb 14, 2020 9:00 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Inks Exclusive License Agreement with University of Pittsburgh for Diabetes Gene Therapy

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, recently announced its entry into an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect approximately 30.3 million people in the U.S., or 9% of the U.S. population. According to the update, Genprex’s licensed diabetes gene therapy technology is designed to reprogram alpha cells in the pancreas into beta-like cells, restoring their function, thereby replenishing insulin levels. “We are…

Continue Reading

TuesdayFeb 11, 2020 11:53 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Enters Exclusive License Agreement with University of Pittsburgh for Potentially Curative Gene Therapy Candidate for Diabetes

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, today announced its entry into an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect approximately 30.3 million people in the U.S., or 9% of the U.S. population. According to the update, Genprex’s licensed diabetes gene therapy technology is designed to reprogram alpha cells in the pancreas into beta-like cells, restoring their function, thereby replenishing insulin levels. “We are…

Continue Reading

ThursdayFeb 06, 2020 11:08 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Meets Nasdaq Minimum Bid Price Requirement, Regains Compliance

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced its February 4, 2020 receipt of notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule") for continued listing on The Nasdaq Capital Market. Accordingly, the company has regained compliance with the Bid Price Rule and Nasdaq considers the matter closed. To view the full press release, visit http://nnw.fm/Fi5Dq About Genprex, Inc. Genprex, Inc. is…

Continue Reading

WednesdayFeb 05, 2020 1:37 pm

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Focus Clinical Efforts on Oncoprex(TM) in Combination with Osimertinib for Treatment of Non-Small Cell Lung Cancer

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today provided a clinical update and focus for its Oncoprex(TM) immunogene therapy program for 2020. According to the update, Genprex will prioritize the development of Oncoprex in combination with osimertinib for the treatment of non-small cell lung cancer (“NSCLC”). Genprex, on January 14, 2020, received U.S Food and Drug Administration (“FDA”) Fast Track Designation for its Oncoprex immunogene therapy in combination with the EGFR tyrosine kinase inhibitor osimertinib (AstraZeneca’s Tagrisso(R), currently its highest grossing product) for the…

Continue Reading

WednesdayFeb 05, 2020 11:19 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Launches Innovative Culture Media for Growing Ovarian Tumor Cells in the Lab

Predictive Oncology (NASDAQ: POAI), together with its subsidiary, TumorGenesis, Inc., today announced that it has selected US Biological Corporation of Salem, Massachusetts as the manufacturer and distributor of its innovative culture media for growing ovarian tumor cells. TumorGenesis media are specially formulated to help researchers isolate and maintain the unique histological and basic biological signatures of heterogeneous ovarian cell types while growing them in the laboratory, unlike traditional cell culture media that select for one or two fast growing cell types. “Using these proprietary media our partners have identified 25 cell types from ovarian tumors, which to a large degree…

Continue Reading

MondayFeb 03, 2020 10:56 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at NobleCon16 Investor Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that it will present at the Noble Capital Markets 16th Annual Investor Conference. Genprex’s presentation is scheduled to take place at 1:30 p.m. EST on Monday, February 17, 2020, at the conference to be held at the Seminole Hard Rock Hotel & Casino in Hollywood, Florida from February 16-18, 2020. According to the update, Genprex CEO Rodney Varner will deliver an overview of the Company and provide updates on its product pipeline, including the Food…

Continue Reading

WednesdayJan 29, 2020 10:15 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Independent Research Findings on TUSC2 as a Potential Target and Biomarker for Thyroid Carcinoma

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that, in a recent study, independent researchers reported that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex(TM) immunogene therapy, is a potential target and biomarker for thyroid carcinoma. Genprex has no affiliation with these researchers. The study, published in the International Journal of Molecular Sciences, reports that TUSC2 overexpression decreased thyroid cancer proliferation, migration and invasion. “We continue to be encouraged by data resulting from studies conducted at multiple research institutions…

Continue Reading

TuesdayJan 28, 2020 1:19 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Unique Competitive Advantage

Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company, possesses a unique advantage over its competition in the form of samples and access to historical data on clinical outcomes. This data could enable POAI to produce value to pharmaceutical companies significantly faster than its competitors. An article discussing the company reads, “Specifically, POAI can leverage two unique proprietary assets, from its acquisition of Helomics, which virtually eliminate development risk, a factor that considerably weighs on competitors’ efforts in the precision medicine space. First, Predictive Oncology possesses a clinically validated, tumor-profiling platform built from data derived from actual…

Continue Reading

TuesdayJan 28, 2020 9:18 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Closes $8M At-The-Market Offering

Genprex (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced the closing of its common stock offering priced at-the-market under Nasdaq rules. Genprex sold a total of 7,620,000 shares of its common stock at a price of $1.05 each, resulting in total gross proceeds of $8 million before deducting commissions and estimated offering expenses. The company plans to use the proceeds toward the advancement of its lead clinical programs in non-small cell lung cancer (“NSCLC”) and…

Continue Reading